Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427881 | 1.00 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL27998030 | 0.76 | — | — | |
| SCHEMBL2771341 | 0.71 | — | — | |
| SCHEMBL11349207 | 0.71 | GSK3A (0.37) | GSK3AGSK3B | |
| SCHEMBL791362 | 0.69 | GSK3A (0.36) | GSK3AGSK3B | |
| SCHEMBL13811980 | 0.68 | — | — | |
| SCHEMBL5285232 | 0.68 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL29750384 | 0.68 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL29419946 | 0.68 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL10373645 | 0.68 | GSK3A (0.39) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103304492-B | The synthetic method of a kind of EGFR inhibitor Dacomitinib | HUNAN OUYA BIOLOGICAL CO., LTD. (CN) | 2015-12-23 | — | — | CN | claimed |
| CN-104530063-A | Quinazoline and heterocyclic ring compounds, preparing method of compounds, and application of compounds serving as epidermal growth factor receptor inhibitors used for treating cancer | BEIJING DALITAI PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-04-22 | — | — | CN | claimed |
| US-20260049089-A1 | KRAS INHIBITOR COMPOUND | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-02-19 | — | — | US | disclosed |
| CN-118324761-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4374929-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4323070-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-113767106-B | Oxazaquinazolin-7 (8H) -ones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024022471-A1 | KRAS INHIBITOR COMPOUND | 上海湃隆生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| EP-4281078-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | Lupin Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEO ONCOLOGY INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102711474-A | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2012-10-03 | — | — | CN | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | disclosed |
| WO-1992013092-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF HEMATOPOIETIC GROWTH FACTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| WO-1992013063-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF GROWTH FACTOR GENES AND GROWTH FACTOR RECEPTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | GSK3A 1985/4885GSK3B 1727/4885 |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, PLIN1 | GSK3A 2560/4885GSK3B 2702/4885 |
| US-20260049089-A1 | KRAS INHIBITOR COMPOUND | KRAS, NRAS, HRAS | GSK3A 886/4885GSK3B 905/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | GSK3A 4112/4885GSK3B 4441/4885 |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | GSK3A 1985/4885GSK3B 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.